OVARIAN CANCER RESEARCH FUND INC: Event Information: Managing Recurrence: What you Need to Know Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, November 16, 2016

OVARIAN CANCER RESEARCH FUND INC: Event Information: Managing Recurrence: What you Need to Know



OVARIAN CANCER RESEARCH FUND INC WebEx Enterprise Site

Registration is required to join this event. If you have not registered, please do so now.
Date and time:

Monday, November 28, 2016 6:00 pm
Eastern Standard Time (New York, GMT-05:00)
Change time zone
Duration: 1 hour
Description:
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation Dr. Sarah Adams will give an overview of strategies for managing recurrent ovarian cancer. She will discuss the goals of treatment during recurrence, typical courses of treatment, and offer advice on how to approach making decisions about treatment during recurrence.

Dr. Sarah Adams joined the faculty of the University of New Mexico Cancer Center in 2102, where she is an Assistant Professor, and the Surface Professor in Ovarian Cancer Research in the Department of Obstetrics and Gynecology. Prior to her recruitment to the University of New Mexico, she spent several years at the University of Pennsylvania. Her undergraduate degree is from Harvard University, and she completed medical school and a residency in obstetrics and gynecology at the University of Chicago. In addition to being a skilled physician, Dr. Adams is also an accomplished researcher. She is a 2011 recipient of OCRFA’s prestigious Liz Tilberis Award. In addition to OCRF, her work has been supported by grants from the Gynecologic Cancer Foundation, the Sandy Rollman Foundation, the Kaleidoscope of Hope Foundation, the Ovarian Cancer SPORE through the Fox Chase Cancer Center, and the American Society of Clinical Oncology with a Young Investigator’s Award.




0 comments :

Post a Comment

Your comments?